# Synthesis and Serotonergic Activity of Arylpiperazide Derivatives of Serotonin: Potent Agonists for 5-HT<sub>1D</sub> Receptors

Michel Perez, Catherine Fourrier, Isabelle Sigogneau, Petrus J. Pauwels, Christiane Palmier, Gareth W. John, Jean-Pierre Valentin, and Serge Halazy\*

Medicinal Chemistry Division, Cellular and Molecular Neurobiology, Laboratory and Cardiovascular Diseases Division, Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, 81106 Castres Cédex, France

Received May 8, 1995\*

A series of new arylpiperazide derivatives of serotonin has been prepared and evaluated as  $5\text{-HT}_{1D}$  receptor agonists. Binding experiments at cloned human  $5\text{-HT}_{1D\alpha}$ ,  $5\text{-HT}_{1D\beta}$ , and  $5\text{-HT}_{1A}$  receptors show that all the compounds are very potent and selective ligands for  $5\text{-HT}_{1D}$  receptor subtypes. Functional activity studies (contraction of the New Zealand white rabbit saphenous vein) demonstrate that most of the derivatives behave as full agonists. Among them, the aryl sulfonamide derivative **5q** (p $D_2$  = 8.33 compare to 5.75 for sumatriptan) was also identified as a very potent agonist in inhibiting the forskolin-mediated cyclase coupled to  $5\text{-HT}_{1D\beta}$  receptors (EC<sub>50</sub> = 0.52 nM).

5-RT 1

A migraine is a common neurological disorder that can severely affect quality of life and daily functioning. Serotonin (1, Figure 1) has long been implicated in the pathophysiology of migraine,<sup>1</sup> and the recent discovery that a selective 5-HT<sub>1D</sub> receptor agonist such as sumatriptan (2) is a highly effective, rapid-acting, and well-tolerated drug for the treatment of acute attacks of migraine<sup>2</sup> has stimulated extensive research efforts in this area. Very recently, new 5-HT<sub>1D</sub> receptor agonists such as 3 (MK-462) and 4 (311C90) have also been reported<sup>3</sup> to be clinically effective in the treatment of migraine headache, thus confirming the therapeutic potential of this class of compounds. The  $5-HT_{1D}$ receptors belong to the 5-HT<sub>1</sub> subfamily of serotonin receptors<sup>4</sup> and have been recently divided into two further receptor subtypes, both negatively coupled to adenylate cyclase and identified in human tissues as  $5\text{-}HT_{1D\alpha}$  and  $5\text{-}HT_{1D\beta}$  receptors on the basis of molecular biology and cloning studies.<sup>5</sup> To date, no clear functional distinction between 5-HT<sub>1Da</sub> and 5-HT<sub>1Db</sub> receptor subtypes has been reported, and their respective importance in migraine pathology remains to be determined.<sup>6</sup>

From a structural point of view, it is noteworthy that, with the noticeable exception of SR27592,<sup>7</sup> almost all potent and selective 5-HT<sub>1D</sub> agonists reported to date are tryptamine derivatives substituted in position 5 of the indole nucleus. Extensive work has subsequently been done in designing conformationally restricted analogs of the amino ethyl side chain of tryptamine derivatives, leading to promising new selective 5-HT<sub>1D</sub> agonists like naratriptan,<sup>8</sup> BRL56905,<sup>9</sup> or CP-122,288.<sup>10</sup>

From a synthetic point of view, 5-substituted tryptaminergic 5-HT<sub>1D</sub> agonists can be divided into 5-C-, 5-N-, and 5-O-alkylated derivatives; the synthesis and pharmacological properties of 5-C-alkylated tryptamine derivatives have been extensively studied as exemplified not only by the three antimigraine agents 2, 3, or 4 but also by numerous 5-heterocyclic-substituted tryptamine derivatives including L694,247.<sup>11</sup> Recently, some 5-Nsubstituted tryptamine derivatives incorporating a nitropyridyl moiety,<sup>12</sup> as well as some 5-O alkylated MK 462 3  $R_1 = N$  N = N

MeNHSO

Sumatriptan 2

NMe.

NMe,

agonists. The latter molecules are attractive since they can be synthesized from serotonin itself. This, of course, differs considerably from the synthetic chemistry required to prepare 5-C-alkylated tryptamine derivatives. During the course of our studies concerning the identification of new potent, and calenting 5 HT

identification of new, potent, and selective 5-HT<sub>1D</sub> agonists, we have considered the introduction of an arylpiperazide moiety as a 5-O substituent on serotonin in order to design new, easily prepared, potent, and selective 5-HT<sub>1D</sub> agonists. We describe in this paper<sup>15</sup> the synthesis of a series of 5-arylpiperazide derivatives of serotonin of formula 5. In order to explore the structural requirements to achieve high affinity and selective 5-HT<sub>1D</sub> binding, we have studied changes in the arylpiperazide substituent  $(R_1)$  and the length of the linking chain (n). The pharmacological properties of these compounds have been compared to sumatriptan, MK462, and 311C-C90 at the cloned human 5-HT<sub>1Da</sub>, 5-HT<sub>1D $\beta$ </sub>, and 5-HT<sub>1A</sub> receptors, and their agonist potency has been determined in a functional assay based on 5-HT<sub>1D</sub> receptor-mediated contractions in the isolated rabbit saphenous vein.

<sup>&</sup>lt;sup>®</sup> Abstract published in Advance ACS Abstracts, August 1, 1995.

Table 1. Binding Profile at Cloned Human Receptors and Functional Activity of Compounds 1-5

			$K_{ m i}  ({ m nM})^a$		vein contraction		
compd	$\mathbb{R}^1$	n	5-HT1D <sup>a</sup>	5-HT1D <sup>b</sup>	5-HT1A	pD <sub>2</sub> (CI 95%) <sup>b</sup>	rel max <sup>c</sup>
	H	1	1.2	0.4	10.4	7.36 (7.22-7.50)	$0.68 \pm 0.22$
5b	o-Me	1	2.08	0.8	8.0	5.86 (5.40-6.35)	$1.01\pm0.19$
5c	$o-NO_2$	1	0.58	0.30	5.2	6.33 (6.00-6.66)	$0.87 \pm 0.17$
5d	o-CN	1	0.92	0.39	15.0	7.42(7.17 - 7.64)	$1.22\pm0.17$
5f	$p$ -NO $_2$	3	1.2	5.0	15.1	6.91 (6.38-7.31)	$1.06\pm0.18$
5g	$p-NO_2$	1	0.42	0.83	24	6.12(5.54 - 6.64)	$0.52\pm0.15^*$
5h	$p-NO_2$	4	2.5	1.8	15.9	6.74(6.26 - 7.16)	$0.71 \pm 0.17^{*}$
5i	p-NO <sub>2</sub>	5	0.34	0.47	12.8	7.00(6.37 - 7.55)	$0.73\pm0.12$
5j	$p$ -NH $_2$	1	2.92	1.64	607	6.88(6.60-7.08)	$0.83 \pm 0.10$
5k	$p$ -NH $_2$	4	1.4	1.4	50.7	7.05(6.79 - 7.28)	$0.73 \pm 0.11^{*}$
51	$p-\mathrm{NH}_2$	5	0.38	0.31	42.6	8.09 (7.78-8.37)	$0.79\pm0.13$
5 m	<i>p</i> -NHCOPh	1	1.7	1.3	61	7.31(7.17 - 7.46)	$0.90\pm0.11$
5n	p-NHCOMe	1	1.4	2.8	77.8	6.67(6.51 - 6.85)	$1.01\pm0.14$
50	$p -NHSO_2Me$	1	0.56	2.7	68.9	7.62(7.39 - 7.80)	$1.21\pm0.11$
5p	$p-\mathrm{NHSO}_2\mathrm{NMe}_2$	1	0.26	1.9	40.3	7.20 (6.88-7.51)	$0.96\pm0.16$
5q	p-NHSO <sub>2</sub> Me	5	1.30	1.4	10.2	8.33 (7.84-8.65)	$1.05\pm0.18$
5r	p-CH <sub>2</sub> NH <sub>2</sub>	1	0.93	2.5	130	6.80 (6.47-7.14)	$0.92\pm0.18$
5s	$o\operatorname{-CH}_2\operatorname{NH}_2$	1	6.9	1.8	13.6	6.52(6.26 - 6.80)	$0.90\pm0.13$
5t	p-CH <sub>2</sub> NHSO <sub>2</sub> Me	1	1.0	2.2	95	6.92 (6.76-7.09)	$0.88\pm0.18$
5u	o-CH <sub>2</sub> NHSO <sub>2</sub> Me	1	1.8	0.53	5.1	6.00(5.45 - 6.52)	$0.93 \pm 0.20$
1	5-HT		4.8	7.1	2.5	6.95 (6.85-7.06)	$1.00\pm0.05$
2	sumatriptan		8.5	23.1	440	5.75 (5.68-5.87)	$1.26\pm0.06^*$
3	MK462		13.5	40	293	6.15(6.04 - 6.26)	$1.42 \pm 0.11^{*}$
4	311C90		0.92	4	78.6	6.13 (5.91-6.37)	$1.48\pm0.08^*$

<sup>a</sup>  $K_i$  values are given as mean of one or two independent experiments each performed in duplicate. <sup>b</sup> Contraction of the New Zealand white rabbit saphenous vein with confidence interval at 95%. <sup>c</sup> Maximum contraction obtained relative to 5-HT (mean  $\pm$  SEM);\* p < 0.05 versus 5-HT.

Table 2. Physical Properties of Compounds Listed in Table 1

compd	mp,ª °C	formula <sup>b</sup>	anal. <sup>c</sup>
5a	229	C <sub>22</sub> H <sub>26</sub> N <sub>4</sub> O <sub>2</sub> ·2HCl·H <sub>2</sub> O·0.7MeOH	C,H,N
5b	146 - 148	C <sub>23</sub> H <sub>28</sub> N <sub>4</sub> O <sub>2</sub> ·2HCl·1.8H <sub>2</sub> O	C,H,N,Cl*
5c	130	$C_{22}H_{25}N_5O_4$ ·HCl·1.3H <sub>2</sub> O	C,H,N,Cl
5d	107	$C_{23}H_{25}N_5O_2$ ·HCl·1.4H <sub>2</sub> O	C,H,N,Cl
<b>5f</b>	120	$C_{24}H_{29}N_5O_4$ ·HCl·H <sub>2</sub> O	C,H,N,Cl*
5g	225	$C_{22}H_{25}N_5O_4$ ·HCl·H <sub>2</sub> O	C,H,N,Cl
5h	120	$C_{25}H_{31}N_5O_4$ ·HCl·1.7H <sub>2</sub> O	C,H,N,Cl*
5i	100	$C_{26}H_{33}N_5O_4 \cdot 1.1HCl \cdot H_2O$	C,H,N,Cl
5j	196	$C_{22}H_{27}N_5O_2$ ·3HCl·2H <sub>2</sub> O	C,H,N
5k	170	$C_{25}H_{33}N_5O_2$ ·3HCl·1.5H <sub>2</sub> O	C,H,N,Cl*
51	150	$C_{26}H_{35}NO_2$ ·3HCl·1.4H <sub>2</sub> O	C,H,N,Cl*
5m	184 - 185	$C_{29}H_{31}N_5O_3$ ·2HCl·2H <sub>2</sub> O	C,H,N
5n	171	$C_{24}H_{29}N_5O_3$ ·2HCl·1.8H <sub>2</sub> O	C,H,N,Cl
50	229	$C_{23}H_{29}N_5O_4S-2HCl-0.8H_2O$	C,H,N,Cl
5p	170	$C_{24}H_{32}N_6O_4S \cdot 2HCl \cdot 1.5H_2O$	C,H,N,Cl
5q	141	C <sub>27</sub> H <sub>37</sub> N <sub>5</sub> O <sub>4</sub> S•2HCl•0.5H <sub>2</sub> O•0.3EtOH	C,H,N,Cl
5r	185	$C_{23}H_{29}N_5O_2 \cdot 3HCl \cdot 1.5H_2O$	C,H,N,Cl
5s	198	$C_{23}H_{29}N_5O_2 \cdot 3HCl \cdot 1.6H_2O$	C,H,N,Cl*
5t	154	$C_{24}H_{31}N_5O_4S$ ·2HCl- $0.3H_2O$	C,H,N,Cl*
5u	250	$\mathrm{C}_{24}\mathrm{H}_{31}\mathrm{N}_5\mathrm{O}_4\mathrm{S}\text{\cdot}1.5\mathrm{HCl}\text{\cdot}\mathrm{H}_2\mathrm{O}$	C,H,N,Cl

<sup>a</sup> All compounds were crystallized from CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O or CHCl<sub>3</sub>/ Et<sub>2</sub>O. <sup>b</sup> Satisfactory <sup>1</sup>H-NMR were obtained for all compounds. <sup>c</sup> The analyses are within  $\pm 0.4\%$  of the theoretical values (compounds with an asterisk (\*) do not agree with calculated values for Cl possibly due to the accuracy of the method used).

#### Chemistry

All the compounds of formula **5** (Table 1) have been prepared through a linear sequence from serotonin itself.

The synthesis of compounds 5a-d, f-i (Scheme 1) starts by treating the commercially available creatinine salt of 5HT with (BOC)<sub>2</sub>O/NaOH to give N-BOCserotonin **6** in 89% yield. This intermediate was then condensed with the chloro amides 7a-i (prepared by treatment of the corresponding arylpiperazine with the appropriate acid chloride (ClCO(CH<sub>2</sub>)<sub>n</sub>Cl) in the presence of CaCO<sub>3</sub> in methyl ethyl ketone) to give the expected tryptamines 8a-i by one of the two following methods: compounds 8a-g were synthesized by refluxing the solution of N-BOC-serotonin **6** and the appropriate chloro amides 7a-g in MEK (4-6h), in the presence of  $K_2CO_3$  as a base and a catalytic amount of KI. Intermediates **8h**, i were prepared by heating a solution of 6 and 7h, i in DMF (24-66 h) using  $Cs_2CO_3$  as a base. Finally, removal of the BOC protecting group upon reaction with excess TFA in toluene at room temperature afforded the arylpiperazide derivatives of serotonin 5a-d,f-i. The nitro derivatives 8g-i were found to be very interesting synthetic intermediates since, upon reduction by catalytic hydrogenation (hydrogen over Pd/ C), they are easily transformed into the corresponding aniline derivatives 8j-l. These compounds were then deprotected in the conditions described above to give the final products 5j-l or, alternatively, they are used to further modify the arylpiperazine moiety as illustrated in Scheme 2. Thus, treatment of intermediate 8j with methanesulfonyl chloride in pyridine afforded 80 (92% yield). As demonstrated by <sup>1</sup>H-NMR analysis, the methylsulfonylation takes place exclusively at the aniline nitrogen with no sulfonylation observed at the indole nitrogen. The only byproduct (<10%) obtained under these conditions was identified as the bis-sulfonylation product at the aniline nitrogen. Within similar conditions, the aniline derivative 8j can be transformed into the intermediates 8n, 8m, and 8p after reaction with acetic anhydride (73% yield), benzoylchloride (92% yield), and dimethylsulfamoyl chloride (58%), respectively.

By analogy, the nitriles 8d,e were also used as precursors of benzylamine derivatives 8r,s upon catalytic hydrogenation (H<sub>2</sub>, Raney Ni) in THF and ammonia (13/1). These compounds treated with methanesulfonyl chloride in pyridine afforded 8t,u which upon deprotection gave 5t,u (Scheme 3).

All compounds were purified by column chromatography on silica gel. Subsequent treatment of the free amines with HCl in dichloromethane afforded the







#### Scheme 2<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) H<sub>2</sub>, Pd/C, MeOH, 59-99%; (b) PhCOCl, Ac<sub>2</sub>O, MsCl or Me<sub>2</sub>NHSO<sub>2</sub>Cl, pyridine, 0 °C to room temperature, 1-12 h, 58-95%; (c) TFA (excess), toluene, 25 °C, 1 h, 69-99%.

Scheme 3<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) H<sub>2</sub>, Raney Ni, THF/NH<sub>4</sub>OH (13/1), 59-99%; (b) MsCl, pyridine, 0 °C to room temperature, overnight, 97-99%; (c) TFA (excess), toluene, 25 °C, 1 h, 56-93%.

hydrochloride salts of the arylpiperazides derivatives of serotonin **5** suitable for biological evaluation.

## **Results and Discussion**

**Structure**-Affinity Relationships. The binding affinities of compounds 5 and reference compounds have been measured at cloned human 5-HT<sub>1Da</sub>, 5-HT<sub>1Dβ</sub>, and 5-HT<sub>1A</sub> receptors.<sup>16,17</sup> The results obtained are summarized in Table 1. The arylpiperazides derivatives of

serotonin **5** show a very good affinity at both  $5\text{-}HT_{1Da}$ and  $5\text{-}HT_{1D\beta}$  receptors, especially when compared to reference compounds including serotonin itself. The introduction of substituents (H-bond acceptors or donors) on the aromatic ring attached to the piperazine moiety has only very little influence on the binding of these compounds at  $5\text{-}HT_{1D}$  receptors (compare **5a** to **5b-d,g,j,m-p,r-u**), a result which is opposite to the observations of an earlier SAR study concerning C-5-

# Arylpiperazide Derivatives of Serotonin

substituted tryptamine derivatives where the same type of modifications leads to a dramatic increase in affinity.<sup>11d</sup> Similarly, modification of the chain length linking the amide to the tryptamine nucleus have only a small effect on binding (5g vs 5f vs 5h vs 5i). On the contrary, it can be observed from the data of Table 1 that the binding selectivity  $(5-HT_{1D} \text{ vs } 5-HT_{1A})$  is extremely sensitive to the nature of the para substituent (compare 5a to 5g,j,m-p,r,t). This observation is not verified for the ortho position (compare 5a to 5b,c,s,u). Modification of the chain length has some slight but significant effect on the binding at 5-HT<sub>1A</sub> receptor (compare **5g** to 5f,h,i; 5j to 5k,l, 5o to 5q); as a general trend, an increase of the chain length slightly increases the affinity at these receptors. In considering the binding aspect only, compound 51 is among the best 5-HT<sub>1D</sub> ligands described to date with a  $pK_i$  of 9.5 (for both 5-HT<sub>1D</sub> receptor subtypes) and a selectivity over 5-HT<sub>1A</sub> of 142-fold; interestingly enough, compound 5j which is also a (p-aminoaryl)piperazide derivative is the most selective 5-HT<sub>1D $\beta$ </sub> ligand of the series (selectivity = 370).

Functional Activity. The 5-HT<sub>1D</sub> ligands 5, sumatriptan, MK462, 311C90, and 5-HT have been tested in the in vitro New Zealand white rabbit saphenous vein contraction model<sup>18</sup> in order to evaluate their agonist potency. When comparing the maximum effect observed for the compounds of this series with 5-HT, it can be noticed that some compounds behave as partial agonists (5a,g) while other compounds (5b-f and 5m-u) were found to be full agonist.<sup>19</sup> Most of these compounds show a very high potency, as, for example, compound 5q  $(pD_2 = 8.33)$  which is about 2600-fold more potent than sumatriptan and 150-fold more potent than MK462 or 311C90 (under similar conditions). Analysis of the functional activity from a structural point of view shows that changing  $R_1$  from p-NO<sub>2</sub> to p-NH<sub>2</sub> increases the potency of about 1 order of magnitude (compare 5g to 5j and 5i to 5l), and moreover, changing  $R_1$  from p-NH<sub>2</sub> to p-NHSO<sub>2</sub>Me improves again the potency in the two series (n = 1 or 5; compare 5j to 5o and 5l to 5q). The intrinsic activity of the two best compounds of this series, 50 and 5q, was also assessed for their ability to inhibit the forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT<sub>1D $\beta$ </sub> receptors in CHO- $K_1$  cells. Compounds **50** and **5q** were found to be highly efficient 5-HT<sub>1D $\beta$ </sub> receptor agonists with EC<sub>50</sub> values of 6.5 and 0.52 nM, respectively. This represents again a clear improvement when compared to the  $EC_{50}$  values for sumatriptan (40 nM), MK462 (105 nM), and 311C90 (15 nM) under similar conditions.

# Conclusions

A new class of highly potent 5-HT<sub>1D</sub> receptor agonists is described. The synthesis takes advantage of the use of serotonin as starting material to obtain the piperazide derivatives through a short sequence. Binding affinity of compounds of formula **5** is only slightly altered by substitution of the arylpiperazine moiety (R<sub>1</sub>) or by modification of the linker chain length (n), possibly suggesting that a deep pocket is available in the binding domain of the 5-HT<sub>1D</sub> receptors. On the contrary, binding selectivity (versus 5-HT<sub>1A</sub>) and intrinsic activity (as measured by the ability of compounds to contract rabbit saphenous vein) are highly dependent on these structural features, altogether most of the new arylpiperazide derivatives of serotonin 5 compare very favorably with reference compounds as 5-HT<sub>1D</sub> agonists.

## **Experimental Section**

Melting points were recorded on a electrothermal 9200 apparatus and were uncorrected. <sup>1</sup>H NMR spectra were obtained on a Bruker AC200 (200 MHz) instrument. IR spectra were obtained on a Nicolet FT510P. Mass spectra were recorded on a Nermag R10-10B spectrometer. Purification by chromatography refers to flash chromatography on silica gel (0.04-0.063 mm supplied by S.D.S.) with the eluant indicated applied at a pressure of 0.5 atm. Elemental analyses for carbon, hydrogen, and nitrogen were determined with a Fisons EA 1108/CHN instrument.

**Preparation of 3-[2-[N-(***tert***-Butoxycarbonyl)amino]**ethyl]-1*H*-indol-5-ol (6). To a solution of serotonin creatinine sulfate monohydrate (102 g, 252 mmol) in H<sub>2</sub>O (2.1 L) and NaOH 2N (420 mL) was added di-*tert*-butyl dicarbonate (82.6 g, 378 mmol) at room temperature. The mixture was stirred for 1 h, then extracted with EtOAc ( $3 \times 1$  L), and washed with H<sub>2</sub>O. The combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude oil was purified by chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 20/1) to give **6** (65.9 g, 95%): <sup>1</sup>H NMR (DMSOd<sub>6</sub>)  $\delta$  1.38 (s, 9H, tBu), 2.86 (t, 2H, J = 8.2 Hz, CH<sub>2</sub>), 3.45 (dt, 2H, J = 5.4 and 8.2 Hz, CH<sub>2</sub>N), 6.56 (dd, 1H, J = 2.2 and 8.6 Hz, 6-CH), 6.80 (d, 1H, J = 2.2 Hz, 2-CH), 6.87 (t, 1H, J = 5.4 Hz, NHBOC), 7.00 (d, 1H, J = 2.2 Hz, 4-CH), 7.09 (d, 1H, J = 8.6 Hz, 7-CH), 8.57 (s, 1H, OH), 10.45 (d, 1H, J = 2.2 Hz, NH). Anal. (C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>) C, H, N.

General Procedure for the Preparation of Chloro Amides 7a-i. 2-Chloro-1-[4-(4-nitrophenyl)piperazin-1yl]acetamide (7g). A mixture of 4-(4-nitrophenyl)piperazine (30 g, 0.144 mol) and CaCO<sub>3</sub> (43.5 g, 0.432 mol) in methyl ethyl ketone (MEK) (1 L) was treated at 0 °C by chloroacetyl chloride (20.8 mL, 0.26 mol). The mixture was stirred at room temperature overnight and then diluted with EtOAc and filtered through celite. The filtrate was washed with H<sub>2</sub>O and saturated aqueous NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product (39.2 g, 95%) was used for the next step without further purification.

**General Procedures for the Preparation of Serotonin** Derivatives 8a-i. General Method A: 1-[2-[[3-[2-[N-(tert-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yl]oxy]acetyl]-4-(4-nitrophenyl)piperazide (8g). This procedure was used for the preparation of 8a-g. A mixture of N-BOC-serotonin **6** (21.2 g, 76.9 mmol),  $\alpha$ -chloroamide **7g** (39.2g,  $\sim$ 138 mmol), K<sub>2</sub>CO<sub>3</sub> (26.5 g, 192 mmol), and KI (1.2 g, 7.69 mmol) in MEK (880 mL) was refluxed for 16 h. Then the mixture was diluted with EtOAc and filtered through Celite. The filtrate was washed with H<sub>2</sub>O and saturated aqueous NaCl, dried (Na<sub>2</sub>-SO4), and concentrated. The crude product was chromatographed (CH<sub>2</sub>Cl<sub>2</sub>/acetone, 10/1) to give 8g (35.2 g, 87%): <sup>1</sup>H NMR (DMSO- $d_6$ )  $\delta$  1.34 (s, 9H, tBu), 2.71 (t, 2H, J = 7.8 Hz, CH<sub>2</sub>), 3.14 (dt, 2H, J = 5 and 7.8 Hz, CH<sub>2</sub>N), 3.51-3.60 (m, 8H, CH<sub>2</sub>), 4.79 (s, 2H, CH<sub>2</sub>O), 6.75 (dd, 1H, J = 2 and 8.7 Hz, 6-CH), 6.88 (t, 1H, J = 5 Hz, NHBOC), 6.99-7.04 (m, 4H, Ar), 7.08 (d, 1H, J = 2 Hz, 4-CH), 7.20 (d, 1H, J = 8.7 Hz, 7-CH), 8.06 (d, 2H, J = 9.3 Hz, 3',5'-CH), 10.65 (s, 1H, NH).

General Method B: 6-[[3-[2-[N-(tert-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yl]oxy]-1-[4-(4-nitrophenyl)piperazin-1-yl]hexan-1-one (8i). This procedure was used for the preparation of 8h-i. A mixture of compound 6 (1.87 g, 6.77 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (3.3 g, 10.15 mmol) in DMF (11 mL) was stirred for 15 min at room temperature and then treated with 7i (4.14 g, ~12 mmol). The mixture was warmed at 70 °C for 24 h, diluted with EtOAc, washed with H<sub>2</sub>O (2×) and saturated aqueous NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was chromatographed (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc, 2/1) to give 8i (2.52 g, 64%): <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  1.35 (s, 9H, tBu), 1.44-1.72 (m, 6H, CH<sub>2</sub>), 2.36 (t, 2H, J = 7.0 Hz, CH<sub>2</sub>CO), 2.70 (t, 2H, J = 9 Hz, CH<sub>2</sub>), 3.14 (dt, 2H, J = 4.5 and 9 Hz), 3.46 (m, 6H, CH<sub>2</sub>N), 3.57 (m, 4H, CH<sub>2</sub>N), 3.92 (t, 2H, J = 6.2 Hz, CH<sub>2</sub>O), 6.67 (dd, 1H, J = 2.2 and 8.6 Hz, 6-CH), 6.84 (t, 1H, J = 4.5 Hz, NHBOC), 6.94-6.98 (m, 3H, CH), 7.04 (d, 1H, J = 2.2 Hz, 4-CH), 7.17 (d, 1H, J = 8.6 Hz, 7-CH), 8.03 (d, 2H, J = 9.4 Hz, 3',5'-CH), 10.58 (s, 1H, NH).

General Procedure for the Deprotection of Compounds 8 To Give 5: 1-[2-[[3-(2-Aminoethyl)-1H-indol-5yl]oxy]acetyl]-4-(4-nitrophenyl)piperazide] (5g). Compound 8g (1.55 g, 2.96 mmol) in toluene (40 mL) was treated with excess TFA (5.3 mL) at 25 °C. After 1 h, the mixture was diluted with  $CH_2Cl_2$ , washed with NaOH (2N) and  $H_2O$ , dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by chromatography (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH, 80/19/1) to give 5g (839 mg, 67%) isolated as the hydrochloride salt: mp 225 °C, <sup>1</sup>H NMR (DMSO- $d_6$ )  $\delta$  2.97 (m, 4H, CH<sub>2</sub>), 3.58 (m, 8H, CH<sub>2</sub>), 4.81 (s, 2H, CH<sub>2</sub>O), 6.77 (dd, 1H, J = 2.2 and 8.6 Hz, 6-CH), 7.00 (d, 2H, J = 9.4 Hz, 2',6'-CH), 7.17 (m, 2H, CH), 7.24 (d, 2H, J = 8.8 Hz, 7-CH), 8.05 (d, 2H, J = 9.4 Hz, 3',5'-CH), 8.07 (broad s, 3H, NH<sub>3</sub><sup>+</sup>), 10.84 (s, 1H, NH). Anal ( $C_{22}H_{26}N_5O_4Cl\cdot H_2O$ ) C, H, N, Cl.

General Procedure for the Reduction of Nitro Compounds 8g-i To Give 8j-l: 1-[2-[[3-[2-[N-(tert-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yl]oxy]acetyl]-4-(4-aminophenyl)piperazide] (8j). Compound 8g (5 g, 9.55 mmol) in suspension in MeOH (300 mL) was hydrogenated over Pd/C (10%) (500 mg, 0.47 mmol) under 1 atm of H<sub>2</sub> at room temperature for 9 h. The mixture was filtered through Celite, and the filtrate was concentrated. The crude product was chromatographed (CH<sub>2</sub>Cl<sub>2</sub>/Acetone, 3/1, + 0.2% Et<sub>3</sub>N) to give 8j (2.78 g, 59%): <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.42 (s, 9H, tBu), 2.89 (t,  $2H, J = 7.0 Hz, CH_2), 3.02 (m, 4H, CH_2), 3.42 (m, 2H, CH_2),$ 3.77 (m, 4H, CH<sub>2</sub>), 4.63 (broad s, 1H, NH), 4.75 (s, 2H, CH<sub>2</sub>O), 6.61-6.66 (m, 2H, Ar), 6.76-6.81 (m, 2H, Ar), 6.89 (dd, 1H, J = 2.2 and 8.7 Hz, 6-CH), 7.01 (d, 1H, J = 2 Hz, Ar), 7.09 (d, 1H, J = 2.2 Hz, Ar), 7.25 (d, 1H, J = 8.7 Hz, Ar), 8.08 (s, 1H, NH).

General Procedure for the Reduction of Nitriles 8d,e To Give 8r,s: 1-[2-[[3-[2-[N-(*tert*-butoxycarbonyl)amino]ethyl]-1*H*-indol-5-yl]oxy]acetyl]-4-[4-(aminomethyl)phenyl]piperazide (8r). Compound 8e (800 mg, 1.59 mmol) in solution in a mixture of THF (30 mL) and NH<sub>4</sub>OH (2 mL) was hydrogenated over Raney nickel (catalytic) under 1 atm of H<sub>2</sub> at room temperature for 1.5 day. The mixture was filtered through Celite, and the filtrate was concentrated. The crude product was chromatographed (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 80/19/ 1) to give 8r (804 mg, 99%): <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  1.35 (s, 9H, tBu), 2.71 (t, 2H, J = 8 Hz, CH<sub>2</sub>), 3.05–3.20 (m, 6H, CH<sub>2</sub>), 3.58 (m, 4H, CH<sub>2</sub>), 4.76 (s, 2H, CH<sub>2</sub>O), 6.73 (dd, 1H, J = 2.2and 8.7 Hz, 6-CH), 6.87 (m, 3H, Ar + NHBOC), 7.01 (d, 1H, J= 2 Hz, Ar), 7.07 (d, 1H, J = 2 Hz, Ar), 7.13–7.22 (m, 3H, Ar), 10.65 (s, 1H, NH).

General Procedure for Sulfonylation or Acylation of Compounds 8j,l,r,s To Give 8m-p,t,u: N-[4-[4-[2-[[3-[2-[N-(*tert*-Butoxycarbonyl)amino]ethyl]-1H-indol-5-yl]oxy]acetyl]piperazin-1-yl]phenyl]methanesulfonamide (8o).Compound 8j (2 g, 4.05 mmol) in pyridine (54 mL) was treatedwith methanesulfonyl chloride (0.31 mL, 4.05 mmol) at 0 °C.The reaction mixture was stirred from 0 °C to room temperature for 1 h, diluted with EtOAc, washed with saturatedCuSO<sub>4</sub>, H<sub>2</sub>O, and saturated aqueous NaCl, dried (Na<sub>2</sub>SO<sub>4</sub>), andconcentrated to give the pure compound 8o (2.09 g, 90%): <sup>1</sup>H $NMR (DMSO-d<sub>6</sub>) <math>\delta$  1.35 (s, 9H, tBu), 2.71 (t, 2H, J = 7.8 Hz, CH<sub>2</sub>), 2.84 (s, 3H, CH<sub>3</sub>SO<sub>2</sub>), 3.14 (m, 6H, CH<sub>2</sub>), 3.62 (m, 4H, CH<sub>2</sub>), 6.74 (dd, 1H, J = 2.3 and 8.7 Hz, 6-CH), 6.85–6.94 (m, 3H, Ar + NHBOC), 7.02-7.10 (m, 4H, Ar), 7.20 (d, 1H, J = 8.7Hz, Ar), 9.28 (s, 1H, NHSO<sub>2</sub>), 10.65 (s, 1H, NH).

**Biological Methods.** Male New Zealand white rabbits (ESD, France) weighing 2.2–3.1 kg were killed by overdose of intravenous pentobarbital sodium (Sanofi Laboratories, France). The right and left lateral saphenous veins were cleaned of surrounding fat and connective tissue *in situ*. The veins were excised, placed in cold oxygenated Krebs-bicarbonate buffer solution, and then cut into rings approximatively 5 mm in length. The buffer solution used for preparing the vascular rings and the organ bath studies had the following composition (mM): 118 NaCl, 4.7 KCl, 1.2 MgSO<sub>4</sub>, 2.5 CaCl<sub>2</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 10 D-(+)-glucose. In addition, the solution contained (M): idazoxan (10<sup>-6</sup>), indomethacin (10<sup>-5</sup>), ketanserin (10<sup>-7</sup>), pargyline (10<sup>-6</sup>), prazosin (10<sup>-5</sup>) and N<sup>\omega</sup>-nitro-

L-arginine methyl ester (L-NAME;  $10^{-5}$ ). Each ring was suspended between two stainless steel wire hooks and mounted in an organ bath filled with 20 mL of Krebs-bicarbonate solution maintained at 37 °C and continuously gassed with 95%  $O_2$  and 5%  $CO_2$ . Changes in isometric force were measured by means of a transducer (Statham) connected to an amplifier (Gould Instruments, France) and a computerized data acquisition system (AcqKnowledge, BIOPAC Systems, Inc., Goleta, CA). Following tension adjustments for stress relaxation and a 15 min stabilization period, tissues were successively challenged with a submaximal concentration of KCl (50 mM) and 5-HT ( $10^{-6}$  M) in order to provide a reference contraction by which subsequent agonist concentration-effect curves could be normalized. After recovery from these initial challenges, cumulative concentration-effect curves to the different agonists (1 nM-0.1 mM) were constructed. One concentration-effect curve was carried out per ring.

**Calculations and Logistic Curve Fitting.** Concentration-response curve fitting was performed using the nonlinear least-square algorithm of Marquardt.<sup>20</sup>  $pD_2 = -\log EC_{50}$  where  $EC_{50}$  refers to the geometric mean agonist concentration (with 95% confidence intervals in parentheses) inducing 50% of its maximal effect. Maximum contractions were compared to 5-HT using one way analysis of variance followed by the Fisher test as posthoc test (StatView, Abacus Concepts, Inc., Berkeley, CA).

Acknowledgment. The authors wish to thank Elisabeth Dupeyron for preparing the manuscript.

### References

- Silberstein, S. D. Serotonin (5-HT) and migraine. Headache 1994, 34, 408-417.
   Feniuk, W.; Humphrey, P. P. A. The development of a highly
- Feniuk, W.; Humphrey, P. P. A. The development of a highly selective 5-HT<sub>1</sub> receptor agonist, sumatriptan, for the treatment of migraine. *Drug Dev. Res.* 1992, 26, 235-240.
   Results reported at the 10th International Migraine Trust
- (3) Results reported at the 10th International Migraine Trust Meeting in London (September 1994); cf. SCRIP 1994, 1957, 26.
   (4) Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G.
- (4) Hoyer, D.; Clarke, D. É.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. *Pharmacol. Rev.* **1994**, *46*, 157-203.
- (5) Saudou, F.; Hen, R. 5-HT receptor subtype: Molecular and functional diversity. Med Chem Res 1994, 4, 16-84.
- (6) (a) Hamel, E.; Grégoire, L.; Lau, B. 5-HT<sub>1</sub> receptors mediating contraction in bovine cerebral arteries: a model for human cerebrovascular "5-HT<sub>1Dβ</sub>" receptors. *Eur. J. Phamacol.* 1993, 242, 75-82. (b) Kaumann, A. J.; Parsons, A. A.; Brown, A. M. Human arterial constrictor serotonin receptors *Cardiovas. Res.* 1993, 27, 2094-2103. (c) Rebeck, G. W.; Maynard, K. I.; Hyman, B. T.; Moskowitz, M. A. Selective 5-HT<sub>1Dα</sub> serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. *Proc. Natl. Acad. Sci. U.S.A.* 1994, 91, 3666-3669. (d) Peroutka, S. J. Pharmacological differentiation of human 5-HT<sub>1D</sub> and 5-HT<sub>1D</sub> receptors. *Biol. Signals* 1994, 3, 217-222.
- (7) Frehel, D.; De Cointet, P.; Badorc, A.; Castet, C.; Courregelongue, J.; Despeyroux, P.; Ducros, D.; Guiraudou, P.; Leger, J. M.; Raufaste, D.; Saint-Blancat, A.; Serradeil-Le Gal, C.; Le Fur, Gérard; Maffrand, J. P. SR 27592 and SR 28734: New potent and specific agonists of 5-HT1D receptors. Groupe d'Etude Structure Activité N°XXIII, Annecy, France, 25-28 May 1993.
- and specific agomsts of 5-HT1D receptors. Groupe d'Étude Structure Activité N°XXIII, Annecy, France, 25-28 May 1993.
  (8) Connor, H. E.; O'Shaughnessy, C. T.; Feniuk, W.; Perren, M. J.; North, P. C.; Oxford, A. W.; Butina, D.; Owen, M.; Humphrey, P. P. A. GR85548: a potent selective agonist for the intracranial vascular 5-HT<sub>1</sub> receptor. Proc. Br. Pharmacol. Soc. (Jan 5-7, Cambridge) **1993**, Abst C107.
- (9) King, F. D.; Brown, A. M.; Gaster, L. M.; Kaumann, A. J.; Medhurst, A. D.; Parker, S. G.; Parsons, A. A.; Patch, T. L.; Raval, P. (±) 3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationnally restricted analogue of 5-carboxamidotryptamine with selectivity for the servotonin 5-HT<sub>1D</sub> receptor. J. Med. Chem. 1993, 36, 1918-1919.
- (10) (a) Macor, J. E.; Blank, D. H.; Post, R. J.; Ryan, K. The synthesis of a conformationally restricted analog of the anti-migraine drug sumatriptan. *Tetrahedron Lett.* **1992**, *33*, 8011–8014. (b) Lee, W. S.; Moskowitz, M. A. Brain Res. **1993**, *626*, 303–305.
- W. S.; Moskowitz, M. A. Brain Res. 1992, 53, 626, 303-305.
  (11) (a) Castro, J. L.; Baker, R.; Guiblin, A. R.; Hobbs, S. C.; Jenkins, M. R.; Russel, M. G. N.; Beer, M. S.; Stanton, J. A.; Scholey, K.; Hargreaves, R. J.; Graham, M. I.; Matassa, V. G. Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin-2-yl)-methyl]-1-indole and analogues: Agonists for the 5-HT<sub>1D</sub> receptor J. Med. Chem. 1994,

37, 3023-3032. (b) Chen, C. Improved fisher indole reaction for the preparation of N,N-dimethyltryptamines: synthesis of L-695,-894, a potent 5-HT<sub>1D</sub> receptor agonist J. Org. Chem. 1994, 59, 3738-3741. (c) Castro, J. L.; Matassa, V. G.; Broughton, H. B.; Mosley, R. T.; Street, L. J.; Baker, R. Synthesis, biological activity and electrostatic properties of 3-[2-(dimethylamino)-ethyl]-5-[(3-amino-1,2,4-thiadiazol-5-yl)methyl]-1H-indole, a novel 5-HT<sub>1D</sub> receptor agonist. *Bioorg. Med. Chem. Lett.* **1993**, *3*, 993–997. (d) Street, L. J.; Baker, R.; Castro, J. L.; Chambers, M. S.; Guiblin, A. R.; Hobbs, S. C.; Matassa, V. G.; Reeve, A. J.; Beer, M. S.; Middlemiss, D.N.; Noble, A. J.; Stanton, J. A.; Scholey, K.; Hargreaves, R. J. Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: Potent agonists for 5-HT1D recep-

- b-(oxadiazoiy), tryptammes. Fotent agoiness for b-firing rootput tors. J. Med. Chem. 1993, 36, 1529-1538.
  (12) Macor, J. E.; Blank, D. H.; Fox, C. B.; Lebel, L. A.; Newman, M. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Cost, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schmidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schwidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schwidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schwidt, A. W.; Schultz, D. W.; Koe B. E.; Post, R.J.; Ryan, K.; Schwidt, A. W.; Sch K. 5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT<sub>1D</sub> receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT<sub>1D</sub> receptor selectivity. J. Med. Chem. 1994, 37, 2509-2512.
   Boulenguez, P.; Chauveau, J.; Segu, L.; Morel, A.; Delaage, M.;
- Lanoir, J. Pharmacological characterization of serotonin-ocarboxymethyl-glycyl-tyrosinamide, a new selective indolic ligand (ar tox) in Entry Epicy (cyrtyrosinalina (a new selective induce ingana for 5-hydroxytryptamine (5-HT)<sub>1B</sub> and 5-HT1<sub>1D</sub> binding sites. J. Pharmacol. Exp. Ther. **1991**, 259, 1360-1365.
   (14) Glennon, R. A.; Hong, S.-S.; Dukat, M.; Teitler, M.; Davis K. 5-(nonyloxy)tryptamine: A novel high-affinity 5-HT1<sub>Dβ</sub> serotonin
- receptor agonist. J. Med. Chem. 1994, 37, 2828-2830.
- (15) A preliminary account of this work has been published as a communication: Perez, M.; Pauwels, P.; Palmier, C.; John, G.

W.; Valentin, J. P.; Halazy, S. 5-O carboxymethyl piperazide derivatives of serotonin: a new class of potent and selective 5-HT<sub>1D</sub> receptor agonists *Bioorg. Med. Chem. Lett.* **1995**, in press.

- (16) Pauwels, P. J.; Palmier, C; Colpaert, F. C. Cloned human 5-HT<sub>1Dβ</sub> receptors mediating inhibition of cAMP in permanently transfected CHO-K1 cells: pharmacological characterisation of agonists, partial agonists and antagonists. Cell. Pharmacol. 1995, 2.49-57.
- (17) Pauwels, P. J.; Van Gompel, P.; Leysen, J. E. Activity of 5-HT receptor agonists, partial agonists and antagonists at cloned human 5-HT<sub>1A</sub> receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa-cells. Biochem. Pharmacol. 1993, 45, 375-383.
- (18) Martin, G. R.; MacLennan, S. J. Analysis of the 5-HT receptor in rabbit saphenous vein Exemplifies the problems of using exclusion criteria for receptor. Naunyn-Schmiedeb. Arch. Pharmacol. 1990, 342, 111-119.
- (19) In our assay, relative maximum values above 1 (sumatriptan, MK462, 311C90, and 5d,o) were found to be due to the presence of endothelium in the rings of rabbit saphenous vein. Valentin, J.-P.; Bonnafous, R.; Jorand, C.; Perez, M.; Halazy, S.; Colpaert, F. C.; John, G. W. Influence of endothelium and nitric oxide on the contractile responses evoked by 5-HT<sub>1D</sub> receptor agonists in the rabbit isolated saphenous vein. Pharmacol. Res. 1995, 31, 156.
- (20) Marquardt, D. W. An algorithm for least squares estimation of nonlinear parameters. J. Soc. Indust. Appl. Math. 1963, 11, 431.

JM9503409